Immunotherapy for the Treatment of Cancer

Targeting multiple myeloma, triple-negative breast cancer, non-Hodgkin's lymphoma and more with highly potent biopharmaceutical drugs designed for targeted therapy.

View Product Pipeline


GT Biopharma, Inc. a targeted immunotherapies company with close to market treatments for Central Nervous System diseases.


Latest News

GT Biopharma, Inc. Announces Shawn M. Cross, 20-Year Healthcare Investment Banking Industry Veteran, as President and Chief Operating Officer
Nov 16, 2017 • 8:00 EST | Read More

GT Biopharma Announces Approved FDA IND Transfer of Its First TriKE (OXS-3550)
Oct 24, 2017 • 7:00 EDT | Read More


GT Biopharma, Inc. OTCQB: GTBP
Loading... Change
Loading... Volume
Loading... 52 Week Range